Authors:
Recht, A
Edge, SB
Solin, LJ
Robinson, DS
Estabrook, A
Fine, RE
Fleming, GF
Formenti, S
Hudis, C
Kirshner, JJ
Krause, DA
Kuske, RR
Langer, AS
Sledge, GW
Whelan, TJ
Pfister, DG
Citation: A. Recht et al., Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(5), 2001, pp. 1539-1569
Authors:
Van Poznak, C
Seidman, AD
Reidenberg, MM
Moasser, MM
Sklarin, N
Van Zee, K
Borgen, P
Gollub, M
Bacotti, D
Yao, TJ
Bloch, R
Ligueros, M
Sonenberg, M
Norton, L
Hudis, C
Citation: C. Van Poznak et al., Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial, BREAST CANC, 66(3), 2001, pp. 239-248
Authors:
Munster, PN
Buzdar, A
Dhingra, K
Enas, N
Ni, L
Major, M
Melemed, A
Seidman, A
Booser, D
Theriault, R
Norton, L
Hudis, C
Citation: Pn. Munster et al., Phase I study of a third-generation selective estrogen receptor modulator,LY353381.HCl, in metastatic breast cancer, J CL ONCOL, 19(7), 2000, pp. 2002-2009
Authors:
Barakat, RR
Gilewski, TA
Almadrones, L
Saigo, PE
Venkatraman, E
Hudis, C
Hoskins, WJ
Citation: Rr. Barakat et al., Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy, J CL ONCOL, 18(20), 2000, pp. 3459-3463
Authors:
Gilewski, T
Seidman, A
Norton, L
Hudis, C
Citation: T. Gilewski et al., An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel, CANC CHEMOT, 46, 2000, pp. S23-S26
Authors:
Robson, M
Levin, D
Federici, M
Satagopan, J
Bogolminy, F
Heerdt, A
Borgen, P
McCormick, B
Hudis, C
Norton, L
Boyd, J
Offit, K
Citation: M. Robson et al., Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations, J NAT CANC, 91(24), 1999, pp. 2112-2117
Authors:
D'Andrea, G
Fennelly, D
Norton, L
Baselga, J
Gilewski, T
Hudis, C
Moynahan, ME
Raptis, G
Sklarin, N
Surbone, A
Theodoulou, M
Templeton, MA
Yao, TJ
Seidman, AD
Citation: G. D'Andrea et al., Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer, CLIN CANC R, 5(2), 1999, pp. 275-279
Authors:
Hudis, C
Fornier, M
Riccio, L
Lebwohl, D
Crown, J
Gilewski, T
Surbone, A
Currie, V
Seidman, A
Reichman, B
Moynahan, M
Raptis, G
Sklarin, N
Theodoulou, M
Weiselberg, L
Salvaggio, R
Panageas, KS
Yao, TJ
Norton, L
Citation: C. Hudis et al., 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study, J CL ONCOL, 17(4), 1999, pp. 1118-1126
Authors:
Hudis, C
Seidman, A
Baselga, J
Raptis, G
Lebwohl, D
Gilewski, T
Moynahan, M
Sklarin, N
Fennelly, D
Crown, JPA
Surbone, A
Uhlenhopp, M
Riedel, E
Yao, TJ
Norton, L
Citation: C. Hudis et al., Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy, J CL ONCOL, 17(1), 1999, pp. 93-100
Authors:
Liberman, L
Zakowski, MF
Avery, S
Hudis, C
Morris, EA
Abramson, AF
LaTrenta, LR
Glassman, JR
Dershaw, DD
Citation: L. Liberman et al., Complete percutaneous excision of infiltrating carcinoma at stereotactic breast biopsy: How can tumor size be assessed?, AM J ROENTG, 173(5), 1999, pp. 1315-1322